Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Disease-modifying antirheumatic drugs are commonly used to treat rheumatoid arthritis, but prolonged usage often results in drug related toxicity, loss of effi cacy, or both. The molecular mechanisms that might be involved in the development of resistance to such drugs, and strategies to overcome this phenomenon, are outlined.
The leading cause of mortality in patients with systemic sclerosis is scleroderma interstitial lung disease. Leukotrienes and lipoxins are thought to be key mediators of the inflamatory response, and how these lipoxygenase-derived eicosanoids might contribute to the pathogenesis of scleroderma interstitial lung disease is discussed in this article, along with possible approaches for treatment.